This piece is part of a series that dives deeper into the most prevalent themes of this year’s iteration of our flagship research piece, Charting Disruption. This feature focuses on the aging population, as part of a larger Advancing Healthcare section exploring a variety of innovations in the space. For additional insights from the project, please click here.
The healthcare industry stands at a critical inflection point where traditional care delivery models can no longer keep pace with soaring demand. While preventative care approaches have shown promise in managing chronic conditions and improving patient outcomes, the fundamental gap between healthcare supply and demand continues to widen. Technology is emerging as the crucial bridge across this divide, with the healthtech market projected to more than quadruple from approximately $225 billion in 2022 to over $1 trillion by 2032.1
This growth spans four key segments: healthcare analytics and software solutions, tech-enabled consumer healthcare, smart medical devices, and AI-enabled drug discovery. Each of these sectors represents a distinct approach to augmenting provider capacity and streamlining care delivery. While healthcare has historically been cautious in adopting new technologies, mounting pressure to serve an aging population, manage chronic conditions, and improve access to care is accelerating digital transformation across the industry.
Key Takeaways
The healthtech market is on track to quadruple from $225 billion in 2022 to over $1 trillion by 2032, driven by critical needs in provider capacity, aging populations, and chronic disease management.2
Artificial Intelligence is transforming healthcare across multiple fronts, from reducing administrative burdens to accelerating drug discovery.
The healthcare industry is rapidly adopting intelligent devices, exemplified by the dramatic increase in FDA-approved, AI-enabled medical devices from 6 to 950 over the past decade, fundamentally changing both clinical practice and home-based care delivery.3
AI-Enabled Drug Discovery: From Code to Cure
Despite technological advancements, developing a new medicine still takes 10-15 years and costs $1.3 billion on average.4,5 Only one in ten investigational drugs, however, makes it to market.6 By running millions of scenarios, AI software could reduce the cost of preclinical drug development by 20-40% as well as accelerate design and validation of drug candidates up to 15-fold.7,8
The drug development process is complex, requiring careful validation at each stage to ensure that only the most promising candidates advance to clinical trials and FDA review. A flawed assumption or connection made in the early stages can result in years of wasted development time and resources on a drug that ultimately proves ineffective for patients. AI technology offers a solution by enabling researchers to leverage vast amounts of health data to make more informed decisions from the very beginning of the drug development process. This data-driven approach helps identify potential issues earlier and increases the likelihood of selecting successful drug candidates.
The adoption of AI software for drug development promises to benefit three key stakeholders:
Pharmaceutical Companies: The integration of AI could fundamentally improve the economics of drug development. Currently, pharmaceutical companies must invest in hundreds of drug candidates knowing that only a small fraction will reach the market. This means approved drug prices must account for both successful and failed development costs. With AI-enhanced success rates, companies could develop more drugs more efficiently, potentially leading to better returns on investment and more affordable medicines.
AI Drug Discovery Software Providers: These companies are pioneering a rapidly expanding industry. The AI-enabled drug discovery software sector is projected to be the fastest-growing generative AI segment through 2032, with a compound annual growth rate of 121%.9
Smart Medical Devices: Where Hardware Meets Healthcare Innovation
Devices are being deployed across the healthcare system to help scale up supply. These often apply novel software and AI applications to innovative hardware to help fill gaps in care. The FDA has approved approximately 950 AI-enabled medical devices in the United States, a dramatic increase from just 6 approved devices a decade ago.11
Healthcare Analytics & Software Solutions: Breaking Free from the Paper Chase
While medical technology advances rapidly in areas like genomics and surgical robots, fundamental administrative processes remain surprisingly analog. An estimated 80% of U.S. healthcare documentation still travels via fax and traditional mail.20 This disconnect between advanced medical capabilities and outdated administrative processes creates significant challenges for healthcare providers and patients alike:
AI-powered solutions are now bridging this divide through intelligent workflow automation. Advanced natural language processing helps generate clinical documentation, from progress notes to discharge summaries. Smart scheduling systems optimize patient flow while automated pre-authorization tools streamline insurance processes. These innovations extend beyond mere efficiency - they're reshaping how healthcare providers interact with information.
The impact reaches beyond individual practices. By aggregating de-identified clinical data across diverse populations, these platforms create a living knowledge network. Providers can access insights from millions of patient encounters, stay current with emerging research, and make evidence-based decisions aligned with the latest standards of care. This collective intelligence, delivered through privacy-preserving analytics, is establishing a new foundation for medical decision-making.
Tech-Enabled Consumer Healthcare: Healthcare at Your Fingertips
The rise of digital health solutions is fundamentally reshaping how patients access and experience healthcare. The global telemedicine market is projected to reach $280 billion by 2032, reflecting growing demand for convenient, accessible care options.25 While virtual care adoption accelerated during the COVID-19 pandemic, the sector has evolved far beyond basic video consultations.
Digital pharmacies are revolutionizing medication management, with platforms like Hims & Hers now serving over 2 million subscribers.26 These services combine home delivery with AI-powered medication management systems, reducing errors and improving adherence. Meanwhile, online healthcare marketplaces are streamlining how patients find and book care, significantly reducing wait times for specialist appointments.
Emerging hybrid care models blend virtual and in-person services, with a majority of healthcare organizations now offering some form of hybrid care delivery. These solutions particularly benefit chronic condition management, where continuous monitoring and regular provider check-ins can significantly improve outcomes. Remote patient monitoring programs have shown 50% reduction in hospital readmissions for conditions like heart failure and diabetes.27
Conclusion
The convergence of AI, smart devices, and digital platforms is ushering in a new era of healthcare delivery. As these technologies mature, they address fundamental challenges in healthcare access, efficiency, and quality. The healthtech market's projected growth to $1 trillion by 2032 reflects both the scale of current healthcare challenges and the transformative potential of technological solutions.28
This transformation stands to benefit all stakeholders: providers gain efficiency, patients receive more accessible and personalized care, and the healthcare system overall becomes more resilient and adaptable. As these technologies continue to evolve, they will likely reveal new possibilities for improving healthcare delivery that we are only beginning to imagine.
